Physician profile
Mark E Kutner
NPI 1104875277
$33,066.84
in general payments reported to CMS, 2019-2025
78 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $9,572 · 2020: $1,666 · 2021: $2,563 · 2022: $3,154 · 2023: $7,208 · 2024: $5,015 · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,205 · Travel and Lodging: $6,770 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,205.27 |
| Travel and Lodging | $6,769.60 |
| Education | $136.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $7,267.99 | 2019-2024 | |
| Modernatx, INC. | $3,274.67 | 2023-2024 | |
| Pfizer INC. | $3,107.66 | 2019-2025 | |
| Amgen INC. | $2,892.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $2,338.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,865.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,712.18 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Radius Health, INC. | $1,649.10 | 2019 | |
| Abbvie INC. | $896.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $758.92 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $677.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.15 | 2019-2025 | Jardiance, Synjardy, Spiriva |
| Amarin Pharma, INC. | $539.07 | 2019-2021 | |
| Antares Pharma, INC. | $534.33 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $428.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $323.27 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $321.70 | 2021-2025 | |
| Dexcom, INC. | $279.49 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Nestle Healthcare Nutrition INC. | $274.75 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $260.87 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $238.81 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $227.60 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Janssen Pharmaceuticals, INC | $205.79 | 2019-2024 | Spravato, Xarelto |
| Biohaven Pharmaceuticals, INC. | $150.21 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $115.53 | 2019-2025 | Livalo, Zoryve |
| Corcept Therapeutics | $111.89 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $111.32 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $106.03 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $92.26 | 2022 | |
| Averitas Pharma INC. | $88.10 | 2023-2024 | Qutenza |
| Phathom Pharmaceuticals, INC. | $87.35 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $86.88 | 2020-2025 | Nexletol |
| Ardelyx, INC. | $86.84 | 2024-2025 | Ibsrela |
| Currax Pharmaceuticals LLC | $83.19 | 2020-2022 | |
| Insmed, INC. | $82.42 | 2025 | Brinsupri, Arikayce |
| Inspire Medical Systems, INC. | $81.89 | 2024-2025 | Inspire |
| Baxter Healthcare | $75.42 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $74.00 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.38 | 2022-2025 | Xifaxan |
| Sanofi Pasteur INC. | $68.16 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.65 | 2022 | |
| Alnylam Pharmaceuticals INC. | $56.95 | 2024-2025 | Givlaari |
| Halozyme INC | $56.89 | 2023 | |
| Allergan, INC. | $55.95 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $51.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $50.94 | 2021-2022 | |
| Phadia US INC. | $45.67 | 2020-2024 | Immunocap |
| Viatris Specialty LLC | $45.59 | 2025 | Yupelri |
| Biogen, INC. | $41.30 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $37.57 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $36.13 | 2019-2022 | |
| Electromed, INC. | $34.00 | 2019 | |
| Ibsa Pharma INC. | $33.86 | 2021-2023 | Tirosint, Licart |
| Aytu Biopharma, INC. | $33.80 | 2020 | |
| Insulet Corporation | $29.47 | 2025 | Omnipod |
| Edwards Lifesciences Corporation | $28.59 | 2024 | |
| Boston Scientific Corporation | $23.45 | 2022 | |
| Alfasigma USA, INC. | $21.91 | 2022 | |
| Lifescan, INC. | $21.52 | 2022 | |
| Axsome Therapeutics, INC. | $21.16 | 2023 | Auvelity |
| Ambu INC. | $19.76 | 2020 | |
| Coloplast Corp | $14.05 | 2019 | |
| Medtronic Minimed, INC. | $12.65 | 2019 | |
| Shire North American Group INC | $12.58 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.73 | 2019 |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$263,196.05 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kutner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.